The above amendments to the specification and claims do not incorporate new matter into the application as originally filed. Basis for the new claims appears throughout the originally-filed description. Specific basis of the new claims appears at the Description passages cited below.

New claims 61-65 recite methods of using at least two LT-β-R activating agents for treating neoplasia where at least one anti-LT-β-R activating agent is a LT-β-R antibody and the antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793 or the cell line BH.A10, ATCC accession number HB11795, as disclosed at least at Description page 26, line 4 to page 28, line 29.

New claims 66-70 recites pharmaceutical compositions of the invention comprising at least two LT-β-R activating agents where at least one anti-LT-β-R activating agent is a LT-β-R antibody and the antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793 or the cell line BH.A10, ATCC accession number HB11795, as disclosed at least at Description page 26, line 4 to page 28, line 29.

Applicants respectfully solicit early and favorable examination. It is believed that the amended claims are in condition for allowance. If the Examiner believes that a telephone conference would expedite the prosecution of this application, please call the undersigned at (617) 679-2079.

Respectfully submitted,

Date: Aug 16, 2001

Niki Cox, Esq. Reg. No. 42,446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)

CLAIMS PENDING AFTER ENTRY

7. A method for treating or reducing the advancement, severity or effects of neoplasia comprising the step of administering a therapeutically effective amount of at least two LT-β-R activating agents and a pharmaceutically acceptable carrier, wherein at least one LT-β-R activating agent comprises an anti-LT-β-R antibody.

8. The method according to claim 7, wherein the anti- LT-β-R antibody is CBE11.

9. The method according to claim 7, comprising at least two anti- LT-β-R monoclonal antibodies which are directed against non-overlapping epitopes of LT-β-R.

10. The method according to claim 9, wherein one anti- LT-β-R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and another anti- LT-β-R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.

11. The method according to claim 9, wherein one anti- LT-β-R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti- LT-β-R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BKA11, CDH10, and CBE11.

12. The method according to claim 9, wherein one anti- LT-β-R monoclonal antibody is selected from the group consisting of BKA11 and CDH10, and another anti-LT-β-R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, and CBE11.

13. The method according to claim 9, wherein one anti- LT-β-R monoclonal antibody is CBE11, and another anti-LT-β-R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10 and CBE11.

14. The method according to claim 9, wherein at least one anti-LT-β-R monoclonal antibody is CBE11 and at least one anti- LT-β-R monoclonal antibody is BHA10.

15. The method according to claim 9, wherein at least one anti-LT-β-R monoclonal antibody is CBE11 and at least one anti- LT-β-R monoclonal antibody is CDH10.

16. The method according to claim 9, wherein at least one anti-LT-β-R monoclonal antibody is AGH1 and at least one anti- LT-β-R monoclonal antibody is CDH10.

17. The method according to any one of claims 6-16, further comprising IFN-γ.

38. A pharmaceutical composition comprising a therapeutically effective amount of at least two LT-β-R activating agents, and a pharmaceutically acceptable carrier, wherein at least one LT-β-R activating agent comprises an anti- LT-β-R antibody.

39. The pharmaceutical composition according to claim 38, wherein the anti- LT-β-R antibody is a monoclonal antibody.

40. The pharmaceutical composition according to claim 39, wherein the anti- LT-β-R antibody is CBE11.

41. The pharmaceutical composition according to claim 37, wherein at least two LT-β-R R activating agents comprise anti- LT-β-R monoclonal antibodies which are directed against non-overlapping epitopes of LT-β-R.

42. The pharmaceutical composition according to claim 41, wherein one anti- LT-β-R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and another anti-LT-β-R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.

43. The pharmaceutical composition according to claim 41, wherein one anti-LT-β-R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti- LT-β-R monoclonal antibody is selected from the group consisting of AGH1, BDA8, CKA11, CDH10 and CBE11.

44. The pharmaceutical composition according to claim 41, wherein one anti- LT-β-R monoclonal antibody is selected from the group consisting of BKA11 and CDH10, and another anti- LT-β-R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, BCG6, BHA10 and CBE11.

45. The pharmaceutical composition according to claim 41, wherein the anti-LT-β-R monoclonal antibody is CBE11, and another anti-LT-β-R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10 and CBE11.

46. The pharmaceutical composition according to claim 41, wherein at least one anti-LT-β-R monoclonal antibody is CBE11 and at least one anti- LT-β-R monoclonal antibody is BHA10.

47. The pharmaceutical composition according to claim 41, wherein at least one anti-LT-β-R monoclonal antibody is CBE11 and at least one anti- LT-β-R monoclonal antibody is CDH10.

48. The pharmaceutical composition according to claim 41, wherein at least one anti-LT-β-R monoclonal antibody is AGH1 and at least one anti- LT-β-R monoclonal antibody is CDH10.

49. The pharmaceutical composition according to any one of the claims 41-48, further comprising IFN-γ.

61. The method according to claim 7, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

62. The method according to claim 7, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

63. The method according to claim 9, wherein at least one anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793

64. The method according to claim 9, wherein at least one anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

65. The method according to claim 64, further comprising at least one anti- LT-β-R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

66. The pharmaceutical composition according to claim 38, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

67. The pharmaceutical composition according to claim 38, wherein the anti- LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

68. The pharmaceutical composition according to claim 46, wherein at least one anti-LT-β-R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

69. The pharmaceutical composition according to claim 46, wherein at least one anti-LT-β-R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

70. The pharmaceutical composition according to claim 69, further comprising at least one anti- LT-β-R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.